Consistently, 3q gains are most frequently observed in tumors arising in BRCA1 mutation carriers [40,41] and, among sporadic cancers, seen with highest incidence in basal-like tumors (20% of cases, in comparison to 10% of luminal tumors [42]). The gene discussed is BRCA1; the disease is cancer.